作者: Xiao Ling Ni , Long Xia Chen , Heng Zhang , Bo Yang , Shan Xu
DOI: 10.1080/10717544.2017.1384862
关键词: Anticancer drug 、 In vitro 、 Lung cancer 、 Medicine 、 Human lung cancer 、 Epidermal growth factor receptor 、 Pharmacology 、 Gefitinib 、 In vivo 、 Pharmaceutical Science 、 General Medicine
摘要: Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an anticancer drug. It accepted opinion that modifying GEF strong hydrophobicity and poor bioa...